Quarterly Result: Godawari Power & Ispat Ltd
Bhagyashree Vivarekar / 25 Nov 2016

Godawari Power & Ispat Ltd., is currently trading at Rs. 61.95, up by 0.9 points or 1.47% from its earlier closing of Rs. 61.05 on the BSE. The company's net loss for the quarter stands at Rs 45.22 cr against Rs 13.35 cr net loss in Q2FY16, triggered by tax expense of Rs 11.02 cr against tax credit availed in last year’s corresponding quarter.
Technical View:
Godawari Power & Ispat Ltd., is currently trading at Rs. 61.95, up by 0.9 points or 1.47% from its earlier closing of Rs. 61.05 on the BSE.
The scrip has touched a high and low of Rs. 62.2 and Rs. 59.15 respectively, after opening at 59.8. In totality 40788(NSE+BSE) shares have been traded on the counter so far; and the stock is currently trading above its 50 DMA.
Standalone Results Q2FY17:
Godawari Power & Ispat Ltd.’s standalone Q2FY17 results have come in post market hours.
Revenue for the quarter has depleted 10.8% yoy to Rs 364.88 cr, triggered by 11% yoy decline in steel segment.
Godawari's EBITDA for the quarter has diminished by 38.1% yoy to Rs 25.36 cr and EBITDA margins have shrunken by 306 bps yoy to 7% on account of poor operational efficiency.
The company's net loss for the quarter stands at Rs 45.22 cr against Rs 13.35 cr net loss in Q2FY16, triggered by tax expense of Rs 11.02 cr against tax credit availed in last year’s corresponding quarter.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.